A 42867
Latest Information Update: 30 Sep 2005
Price :
$50 *
At a glance
- Originator Biosearch Italia
- Class Antibacterials; Glycopeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
- 03 Oct 1995 Discontinued-Preclinical for Bacterial infections in Italy (Unknown route)